PAREXEL Expands CNS Capabilities
PAREXEL enhances early phase clinical development offering for central nervous system studies.
Boston, MA-, June 17, 2008-PAREXEL International Corporation, a leading global biopharmaceutical services provider, today announced that it is expanding its clinical pharmacology capabilities in the Central Nervous System (CNS) therapeutic area. PAREXEL is enhancing existing services in early phase clinical development by adding pain modeling capabilities and combining traditional pharmacodynamic methods with relevant biomarkers, which are surrogate endpoints used to determine safety and efficacy signals.
"CNS diseases, which are reported to account for one third of the world's disease burden, include neurodegenerative diseases such as Alzheimer's and conditions characterized by chronic pain," said Michelle Middle, corporate vice president and worldwide head, clinical pharmacology, PAREXEL. "Our global team of clinical pharmacology experts with in-depth CNS expertise applies various methodologies and biomarkers to help clients make earlier and more effective decisions regarding CNS treatments, and advance this important and growing area of research."
PAREXEL's dedicated clinical pharmacology services directed at alleviation of pain and related symptoms use neuroscience biomarkers to enhance exploration of safety and efficacy and pharmacokinetic analysis. This expanded approach for a broad range of psychiatry, neuropsychopharmacology, neuroimaging, and neurophysiology clinical studies provides greater information about CNS treatments in early phase development. This expertise is aided by the ability to conduct studies with healthy volunteer and patient populations in a time-efficient manner.
PAREXEL, which is a top provider of expertise-based early phase development services from first-in-man to proof of concept, utilizes strategic locations, state-of-the-art technology, and highly qualified and experienced personnel to optimize time and cost savings for clients. PAREXEL's clinical pharmacology business has more than 550 beds, among the largest capacities worldwide. The company's Clinical Pharmacology Research Units are located in Baltimore, MD, and in Los Angeles and San Diego, CA in the United States; London, UK; Berlin, Germany; and Bloemfontein and George, South Africa. PAREXEL also provides early clinical development programs through a joint venture arrangement with Synchron Research based in India.
For more information about PAREXEL's international clinical pharmacology capabilities, visit: http://www.parexel.com/early_phase.html.
Improving Relationships and Diversifying the Site Selection Process
April 17th 2025In this episode of the Applied Clinical Trials Podcast, Liz Beatty, co-founder and chief strategy officer, Inato, discusses a number of topics around site engagement including community-based sites, the role of technology in improving site/sponsor relationships, how increased operational costs are impacting the industry, and more.
Behind the Buzz: Why Clinical Research Leaders Flock to SCOPE Summit
February 7th 2025In this episode, we meet with Micah Lieberman, Executive Conference Director for SCOPE Summit (Summit for Clinical Ops Executives) at Cambridge Innovation Institute. We will dive deep into the critical role of collaboration within the clinical research ecosystem. How do we bring together diverse stakeholders—sponsors, CROs, clinical trial tech innovators, suppliers, patients, sites, advocacy organizations, investors, and non-profits—to share best practices in trial design, program planning, innovation, and clinical operations? We’ll explore why it’s vital for thought leaders to step beyond their own organizations and learn from others, exchanging ideas that drive advancements in clinical research. Additionally, we’ll discuss the pivotal role of scientific conferences like SCOPE Summit in fostering these essential connections and collaborations, helping shape the future of clinical trials. Join us as we uncover how collective wisdom and cross-industry partnerships are transforming the landscape of clinical research.
FDA-Approved Gene Therapy Beqvez Shows Sustained Efficacy, Safety in Long-Term Hemophilia B Trial
April 17th 2025Beqvez (fidanacogene elaparvovec), an FDA-approved one-time gene therapy for hemophilia B, demonstrated sustained factor IX expression, low bleeding rates, and a favorable safety profile over long-term follow-up.
